| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
ARTICLE |
Prostate Cancer and the Will Rogers Phenomenon
Affiliations of authors: University of Connecticut Health Center, Farmington, CT (PCA, MMS, JF); McGill University, Montreal, PQ, Canada (JAH); St. Francis Hospital and Medical Center, Hartford, CT (GHB, PDHK); University of Southern California, Los Angeles, CA (DFP)
Correspondence to: Peter C. Albertsen, MD, Division of Urology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030–3955 (e-mail: Albertsen{at}nso.uchc.edu).
Background: Information on tumor stage and grade are used to assess cancer prognosis and to produce standardized comparisons of end results over time. Changes in the interpretation of classification schemes can alter the apparent distribution of cancer stage or grade in the absence of a true biologic change. Since the introduction of prostate-specific antigen testing, the reported incidence of low-grade prostate cancer has declined. To determine whether this decline is in part a result of Gleason score reclassification during the same time period, we documented the potential impact of reclassification between 1992 and 2002 on clinical outcomes. Methods: A population-based cohort of 1858 men who were 
75 years of age at diagnosis of prostate cancer in 1990–1992 was assembled retrospectively from the Connecticut Tumor Registry. Histology slides of the diagnostic prostate tissue were retrieved and reread in 2002–2004 by an experienced pathologist blinded to the original Gleason score readings. Prostate cancer mortality rates for the cohort calculated using the original Gleason score readings were compared with those calculated using the contemporary Gleason score readings. Statistical tests were two sided. Results: The contemporary Gleason score readings were statistically significantly higher than the original readings (mean score increased from 5.95 to 6.8; difference = 0.85, 95% confidence interval = 0.79 to 0.91; P<.001). Consequently, the Gleason score–standardized contemporary prostate cancer mortality rate (1.50 deaths per 100 person-years) appeared to be 28% lower than standardized historical rates (2.08 deaths per 100 person-years), even though the overall outcome was unchanged. This apparent improvement in mortality held for all Gleason score categories. Conclusions: In this population, a decline in the reported incidence of low-grade prostate cancers appears to be the result of Gleason score reclassification over the past decade. This reclassification resulted in apparent improvement in clinical outcomes. This finding reflects a statistical artifact known as the Will Rogers phenomenon.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Stage Migration and Grade Inflation in Prostate Cancer: Will Rogers Meets Garrison Keillor
- Ian M. Thompson, Edith Canby-Hagino, and M. Scott Lucia
J Natl Cancer Inst 2005 97: 1236-1237.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  L. A. Mucci, A. Powolny, E. Giovannucci, Z. Liao, S. A. Kenfield, R. Shen, M. J. Stampfer, and S. K. Clinton Prospective Study of Prostate Tumor Angiogenesis and Cancer-Specific Mortality in the Health Professionals Follow-Up Study J. Clin. Oncol., November 20, 2009; 27(33): 5627 - 5633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Stark, G. Judson, J. F. Alderete, V. Mundodi, A. S. Kucknoor, E. L. Giovannucci, E. A. Platz, S. Sutcliffe, K. Fall, T. Kurth, et al. Prospective Study of Trichomonas vaginalis Infection and Prostate Cancer Incidence and Mortality: Physicians' Health Study J Natl Cancer Inst, October 21, 2009; 101(20): 1406 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Lu-Yao, P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin, R. S. DiPaola, M. J. Barry, A. Zietman, M. O'Leary, E. Walker-Corkery, et al. Outcomes of Localized Prostate Cancer Following Conservative Management JAMA, September 16, 2009; 302(11): 1202 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Shao, K. Demissie, W. Shih, A. R. Mehta, M. N. Stein, C. B. Roberts, R. S. DiPaola, and G. L. Lu-Yao Contemporary Risk Profile of Prostate Cancer in the United States J Natl Cancer Inst, September 16, 2009; 101(18): 1280 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Stephenson, M. W. Kattan, J. A. Eastham, F. J. Bianco Jr, O. Yossepowitch, A. J. Vickers, E. A. Klein, D. P. Wood, and P. T. Scardino Prostate Cancer-Specific Mortality After Radical Prostatectomy for Patients Treated in the Prostate-Specific Antigen Era J. Clin. Oncol., September 10, 2009; 27(26): 4300 - 4305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Delbanco and P. C. Albertsen A 72-Year-Old Man With Localized Prostate Cancer--14 Years Later JAMA, September 9, 2009; 302(10): 1105 - 1106. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Stark, S. Perner, M. J. Stampfer, J. A. Sinnott, S. Finn, A. S. Eisenstein, J. Ma, M. Fiorentino, T. Kurth, M. Loda, et al. Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3? J. Clin. Oncol., July 20, 2009; 27(21): 3459 - 3464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Penney, C. A. Salinas, M. Pomerantz, F. R. Schumacher, C. A. Beckwith, G.-S. Lee, W. K. Oh, O. Sartor, E. A. Ostrander, T. Kurth, et al. Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality Clin. Cancer Res., May 1, 2009; 15(9): 3223 - 3230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Fesinmeyer, R. Gulati, S. Zeliadt, N. Weiss, A. R. Kristal, and R. Etzioni Effect of Population Trends in Body Mass Index on Prostate Cancer Incidence and Mortality in the United States Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 808 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Kuroiwa, H Uchino, A Yokomizo, and S Naito Impact of reporting rules of biopsy Gleason score for prostate cancer J. Clin. Pathol., March 1, 2009; 62(3): 260 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Roddam, N. E. Allen, P. Appleby, T. J. Key, L. Ferrucci, H. B. Carter, E. J. Metter, C. Chen, N. S. Weiss, A. Fitzpatrick, et al. Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies Ann Intern Med, October 7, 2008; 149(7): 461 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Wilt SPCG-4: A Needed START to PIVOTal Data to Promote and ProtecT Evidence-Based Prostate Cancer Care J Natl Cancer Inst, August 20, 2008; 100(16): 1123 - 1125. [Full Text] [PDF]
|
|
|
|
|
|
L. A. Mucci, Y. Pawitan, F. Demichelis, K. Fall, J. R. Stark, H.-O. Adami, S.-O. Andersson, O. Andren, A. Eisenstein, L. Holmberg, et al. Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1682 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Barry, D. S. Kaufman, and C.-L. Wu Case 15-2008 -- A 55-Year-Old Man with an Elevated Prostate-Specific Antigen Level and Early-Stage Prostate Cancer N. Engl. J. Med., May 15, 2008; 358(20): 2161 - 2168. [Full Text] [PDF]
|
|
|
|
|
|
L. A. Mucci, Y. Pawitan, F. Demichelis, K. Fall, J. R. Stark, H.-O. Adami, S.-O. Andersson, O. Andren, A. S. Eisenstein, L. Holmberg, et al. Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 249 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Nam, A. Toi, L. H. Klotz, J. Trachtenberg, M. A.S. Jewett, S. Appu, D. A. Loblaw, L. Sugar, S. A. Narod, and M. W. Kattan Assessing Individual Risk for Prostate Cancer J. Clin. Oncol., August 20, 2007; 25(24): 3582 - 3588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rodriguez, S. J. Freedland, A. Deka, E. J. Jacobs, M. L. McCullough, A. V. Patel, M. J. Thun, and E. E. Calle Body Mass Index, Weight Change, and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 63 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Albertsen PSA Testing: Public Policy or Private Penchant? JAMA, November 15, 2006; 296(19): 2371 - 2373. [Full Text] [PDF]
|
|
|
|
 |
|
 L. True, I. Coleman, S. Hawley, C.-Y. Huang, D. Gifford, R. Coleman, T. M. Beer, E. Gelmann, M. Datta, E. Mostaghel, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma PNAS, July 18, 2006; 103(29): 10991 - 10996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Stephenson, P. T. Scardino, J. A. Eastham, F. J. Bianco Jr., Z. A. Dotan, P. A. Fearn, and M. W. Kattan Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst, May 17, 2006; 98(10): 715 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Thompson, E. Canby-Hagino, and M. S. Lucia Stage Migration and Grade Inflation in Prostate Cancer: Will Rogers Meets Garrison Keillor J Natl Cancer Inst, September 7, 2005; 97(17): 1236 - 1237. [Full Text] [PDF]
|
|